Trials with mice in whom the researchers implanted human glioblastoma cells have already shown that the treatment is very ...

Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025 ...

Biomednewsbreaks CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances Glioblastoma Treatment With Berubicin Amid Strong Financial Position ...

Presented positive ReSPECT-GBM Phase 1/2 Trial update data at the 2024 Congress of Neurological Surgeons Annual Conference, ...

A new study identifies key genetic vulnerabilities in glioblastoma stem cells, revealing subtype-specific dependencies that ...

Researchers have developed an innovative CAR T-cell therapy to combat glioblastoma, the most common malignant brain tumor in ...

Inovio Pharmaceuticals ( INO -3.64%) Q3 2024 Earnings Call Nov 14, 2024, 4:30 p.m. ET ...

Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented positive ReS ...

Cooperative housing societies (CHS/Society) often encounter unique legal and procedural challenges when managing shared ...

Despite a decrease in cash reserves, Plus Therapeutics Inc (PSTV) reports progress in clinical trials and secures significant ...

Six main cell types form glioblastomas (GBM), the most aggressive brain cancer due to its high rate of recurrence. Of these six, quiescent cancer stem cells are responsible for resistance to therapy ...

Two sisters who lost their dad to an incurable brain tumour, along with their mother, have dedicated two days of research in ...